DHR vs INTC: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Intel Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Intel Corporation · Technology
$133.99
-5.2% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
INTC |
| Current Price |
$177.17 |
$133.99 |
| Fair Value Estimate |
$192.90 |
$126.97 |
| Upside to Fair Value |
+8.9%
|
-5.2%
|
| Market Cap |
$125.4B |
$673.4B |
| Forward P/E |
34.1x
|
-216.1x
|
| EV / EBITDA |
20.8x
|
61.5x
|
| Price / Sales |
5.1x
|
12.5x
|
| Price / FCF |
23.7x
|
-215.9x
|
| Revenue Growth YoY |
+3.7%
|
+7.2%
|
| Gross Margin |
60.7%
|
35.4%
|
| Operating Margin |
21.0%
|
-9.4%
|
| Return on Equity |
7.1%
|
-3.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Intel Corporation is a leading semiconductor company operating primarily in the technology sector with a focus on semiconductors. The business quality is currently challenged due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and operating margin of -9.4%. Despite a sizable market cap of $1678.9 billion and reven…
Accumulation Zones
| Metric |
DHR |
INTC |
| Zone Low |
$144.68 |
$95.23 |
| Zone High |
$163.97 |
$107.92 |
| In Buy Zone? |
No
|
No
|